Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Aurinia Pharmaceuticals (AUPH) Prices 22.3M Shares at $6.75
-
Aurinia Prices US$150.5 Million Public Offering of Common Shares
-
Flexion Therapeutics (FLXN): Focus on PDUFA and Launch - Cantor
-
Cantor Fitzgerald Remains Bullish on Bellicum Pharma (BLCM) Following 4Q
-
Corbus Pharma (CRBP): Thoughts From R&D Day - Cantor
-
Aurinia Pharmaceuticals (AUPH) Reports Public Offering of Common Shares
-
Aurinia Announces Public Offering of Common Shares
-
Harmony Merger (HRMN) Agrees to Merger with NextDecade
-
Harmony and NextDecade Agree to Pursue Merger; NextDecade a Leader among U.S. LNG Project Developers
-
FinTech Acquisition Corp. II Common Stock and Warrants to Commence Trading Separately on March 13, 2017
-
Cantor Fitzgerald Reiterates Overweight on CardConnect Corp. (CCN)
-
Egalet Ltd (EGLT) PT Lowered to $13 at Cantor Fitzgerald Following 4Q
-
Corvus Pharma (CRVS): Update From R&D Day - Cantor Fitzgerald
-
Harmony Merger Corp. Announces Resolution of Dispute and Formal Termination of Merger Agreement with MUNDOmedia
-
Cantor Fitzgerald Reiterates Overweight on Aquinox Pharma (AQXP) Following 4Q
-
Matlin & Partners Acquisition Corporation Announces Pricing of $300,000,000 Initial Public Offering
-
Cantor Fitzgerald Reiterates Overweight Rating and $85 PT on Centene (CNC) Following PA Contract Delay; No Change to Positive Outlook
-
Cantor Fitzgerald Remains Sidelined on IBM (IBM)
-
Cantor Fitzgerald Reiterates Overweight on T2 Biosystems (TTOO) Following CFO Resignation
-
Cantor Fitzgerald Reiterates Overweight Rating and $16 PT OncoMed Pharma (OMED); 'Multiple Candidates Diversify Risk'
-
Imperial Capital Hires Three Senior Investment Grade Sales Professionals Expanding its Credit Sales & Trading Business
-
Orchid Island Capital Announces March 2017 Monthly Dividend and February 28, 2017 RMBS Portfolio Characteristics
-
Health Insurance Innovations (HIIQ) Prices 3M Secondary Public Offering at $14/Share
-
Health Insurance Innovations, Inc. Announces Pricing of Secondary Public Offering by Selling Stockholders
-
Cantor Fitzgerald Remains Bullish on Cerus (CERS) Following 4Q
-
Cantor Fitzgerald Remains Sidelined on CafePress (PRSS) Following 4Q
-
Aerie Pharma (AERI) PT Raised to $56 at Cantor Fitzgerald
-
Hooper Holmes (HH) to Merge with Provant Health Solutions LLC
-
Hooper Holmes and Provant to Merge
-
Health Insurance Innovations (HIIQ) Announces Launch of Secondary Public Offering
-
Health Insurance Innovations, Inc. Announces Launch of Secondary Public Offering by Selling Stockholders
-
Cerus Corporation Reports Fourth Quarter and Year End 2016 Results
-
Supernus Pharma (SUPN): Trokendi XR Settlement Removes a Minor Overhang - Cantor
-
Supernus Pharma (SUPN): Trokendi XR Settlement Removes a Minor Overhang - Cantor
-
Chatham Lodging Trust (CLDT): Houston and Western PA Remain Soft - Cantor
-
Cantor Fitzgerald Remains Sidelined on Eastgroup Properties (EGP) After Adjusting Estimates
-
Omnicell (OMCL) PT Raised to $43 at Cantor Fitzgerald
-
Lipocine (LPCN) Enters Sales Agreement to Offer Up to $20M in Common Stock
-
Omnicell (OMCL) PT Raised to $43 at Cantor Fitzgerald Following Increased Visibility into XT Launch; 'Higher Rev Growth, Improved Margins'
-
Cantor Fitzgerald Reiterates Overweight Rating and $15 PT on NantHealth (NH); 'L-T Outlook is Attractive'
-
TherapeuticsMD (TXMD): Investor Day Recap - Cantor
-
Paratek Pharmaceuticals (PRTK): Earnings Behind Us, Look To Upcoming Readouts - Cantor
-
AMAG Pharmaceuticals (AMAG) PT Raised to $25 at Cantor Fitzgerald on Value of Intrarosa Upside;
-
Cantor Fitzgerald Remains Bullish on Five Star Quality Care (FVE) Following 4Q
-
Odebrecht bonds slump as scandal spillover fans investor skepticism
-
Prothena Corp. (PRTA) Prices 2.7M Offering at $57.50/Share
-
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares
-
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares
-
Cantor Fitzgerald Remains Bullish on Waters Corp. (WAT) Following Investor Day
-
Regulus Therapeutics (RGLS) PT Lowered to $4 at Cantor Fitzgerald; Expect RG-101 Decision in 4Q17

